Ross Osborn
Stock Analyst at Cantor Fitzgerald
(3.11)
# 1,237
Out of 4,735 analysts
99
Total ratings
41.86%
Success rate
2.18%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRE Prenetics Global | Reiterates: Overweight | $9 | $6.00 | +50.00% | 7 | Jan 16, 2025 | |
| XGN Exagen | Reiterates: Overweight | $8 | $4.01 | +99.50% | 5 | Jan 13, 2025 | |
| AVR Anteris Technologies Global | Initiates: Overweight | $9 | $5.88 | +53.06% | 1 | Jan 7, 2025 | |
| RCEL AVITA Medical | Reiterates: Overweight | $21 | $8.73 | +140.55% | 10 | Dec 24, 2024 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $11 → $12 | $8.38 | +43.20% | 10 | Dec 6, 2024 | |
| LUCD Lucid Diagnostics | Maintains: Overweight | $3 → $2 | $0.85 | +135.32% | 4 | Nov 15, 2024 | |
| ELUT Elutia | Reiterates: Overweight | $10 | $3.25 | +207.69% | 9 | Nov 15, 2024 | |
| NYXH Nyxoah | Reiterates: Overweight | $16 | $10.83 | +47.74% | 4 | Nov 5, 2024 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $14 | $18.40 | -23.91% | 2 | Oct 23, 2024 | |
| LMAT LeMaitre Vascular | Initiates: Neutral | $96 | $99.65 | -3.66% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $13.06 | +37.83% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.70 | +105.88% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $9.14 | +20.35% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.63 | +296.83% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $44 | $34.00 | +29.41% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.85 | +116.22% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.90 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.3 | $0.49 | +573.33% | 5 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.53 | +41.64% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 | $17.29 | +44.59% | 7 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $12 | $18.97 | -36.74% | 2 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.65 | +1,224.62% | 2 | Aug 18, 2023 |
Prenetics Global
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $6.00
Upside: +50.00%
Exagen
Jan 13, 2025
Reiterates: Overweight
Price Target: $8
Current: $4.01
Upside: +99.50%
Anteris Technologies Global
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $5.88
Upside: +53.06%
AVITA Medical
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $8.73
Upside: +140.55%
Nano-X Imaging
Dec 6, 2024
Maintains: Overweight
Price Target: $11 → $12
Current: $8.38
Upside: +43.20%
Lucid Diagnostics
Nov 15, 2024
Maintains: Overweight
Price Target: $3 → $2
Current: $0.85
Upside: +135.32%
Elutia
Nov 15, 2024
Reiterates: Overweight
Price Target: $10
Current: $3.25
Upside: +207.69%
Nyxoah
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $10.83
Upside: +47.74%
CVRx, Inc.
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $18.40
Upside: -23.91%
LeMaitre Vascular
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $99.65
Upside: -3.66%
Aug 14, 2024
Reiterates: Overweight
Price Target: $18
Current: $13.06
Upside: +37.83%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.70
Upside: +105.88%
Aug 1, 2024
Reiterates: Overweight
Price Target: $11
Current: $9.14
Upside: +20.35%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.63
Upside: +296.83%
May 15, 2024
Reiterates: Overweight
Price Target: $44
Current: $34.00
Upside: +29.41%
May 3, 2024
Maintains: Overweight
Price Target: $3 → $4
Current: $1.85
Upside: +116.22%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.90
Upside: -
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $0.49
Upside: +573.33%
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.53
Upside: +41.64%
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $17.29
Upside: +44.59%
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $18.97
Upside: -36.74%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.65
Upside: +1,224.62%